Jim Allison and Pam Sharma back a Canadian AI upstart seeking to solve the tumor stroma puzzle
A new company out of Toronto is seeking to put AI and machine learning to the test, using the advanced technology to identify targets in solid cancers and other challenging diseases. And it has the backing of the industry’s resident power couple.
Phenomic AI officially launched Wednesday with $6 million in seed funding and announced that Jim Allison and Pam Sharma have joined its scientific advisory board. The biotech is also bringing on new CSO Mike Briskin, who has a professional history with Allison and Sharma after working with them and Third Rock Ventures to found Jounce Therapeutics about a decade ago.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.